Type 2 Pill May Benefit Those With Type 1
People with type 1 diabetes must take insulin, but could they also benefit from adding a pill that’s used to treat type 2 diabetes? Researchers examined this in two studies that tested two diabetes drugs in the SGLT-2 inhibitor class—the already available dapagliflozin (Farxiga) in one and an investigational drug called sotagliflozin in the other—in addition to insulin in more than 2,200 people with type 1 diabetes who weren’t hitting their glucose targets. Both drugs, which help the kidneys release excess glucose into the urine instead of reabsorbing the glucose, improved blood glucose levels and also produced some weight loss. But sotagliflozin also increased the risk for diabetic ketoacidosis (DKA), a serious condition that occurs when the body doesn’t have adequate insulin and burns fat instead of glucose for fuel. Other SGLT-2 inhibitors are associated with DKA, even when blood glucose levels are in the normal range. More information on the risks and benefits of these drugs is needed before they’re routinely used in people with type 1.
Sources: The New England Journal of Medicine, published online Sept. 13, 2017, and The Lancet Diabetes & Endocrinology, published online Sept. 14, 2017